National Institute on Drug Abuse Updates Website, Now has “Marijuana as Medicine” Page

Bills that would legalize medical cannabis have been filed in West Virginia’s House of Delegates and Senate.

March 06, 2017

Delegate Mike Pushkin (D) filed House Bill 2677, and Senator Richard Ojeda (D) filed Senate Bill 386. Both would legalize medical cannabis, albeit in different manners. HB 2688 has no cosponsors, whereas SB 386 is cosponsored by a bipartisan coalition of nine senators.

HB 2677 would legalize the possession of up to six ounces of cannabis, and the cultivation of up to 12 plants, for those with a qualifying condition who receive a recommendation from a physician. Qualifying conditions include:

(A) Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, Crohn’s disease, agitation of Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, anxiety, addiction to opiates or amphetamines or the treatment of these conditions;

(B) A chronic or debilitating disease or medical condition or its treatment that produces one or more of the following: Cachexia or wasting syndrome; severe or chronic pain; severe nausea; seizures; or severe and persistent muscle spasms, including, but not limited to, those characteristic of multiple sclerosis; or

(C) Any other medical condition or its treatment added by the department, as provided in section six of this article.

The proposal would established a system of licensed and regulated cannabis dispensaries, as a means of safe access to the medicine.

SB 386 would also legalize medical cannabis – including license dispensaries – but in a more limited way. Qualifying conditions include:

(A) A chronic or debilitating disease or medical condition that results in a patient being admitted into hospice or receiving palliative care; or

(B) A chronic or debilitating disease or medical condition or the treatment of a chronic or debilitating disease or medical condition that produces:

(i) Cachexia, anorexia, or wasting syndrome;

(ii) Severe or chronic pain that does not find effective relief through standard pain medication;

(iii) Severe nausea;

(iv) Seizures; or

(v) Severe or persistent muscle spasms.

 

HB 2677 has been assigned to the House Prevention and Treatment of Substance Abuse Committee. SB 386 has been assigned to the Senate Health and Human Resources.

New Hampshire’s House Criminal Justice and Public Safety Committee has passed a bill to decriminalize cannabis and hash possession.

New Hampshire’s House Criminal Justice and Public Safety Committee has passed a bill to decriminalize cannabis and hash possession.

House Bill 640 was approved with an overwhelming 14 to 2 vote. The measure would decriminalize the possession of up to an ounce of cannabis, and up to five grams of hash, for those 21 and older.

If police do catch someone possessing cannabis or hash within those limits, it would be “a fine of $100 for a first offense under this paragraph, a fine of $200 for a second offense within three years of the first offense, or a fine of $350 for a third or subsequent offense within 3 years of 2 other offenses.” Under current law the possession of even a minuscule amount of cannabis is a misdemeanor punishable by up to a year in jail.

House Bill 640 is sponsored by a bipartisan, bicameral coalition of a dozen lawmakers including Representatives Robert Cushing (D), Keith Murphy (R), Frank Sapareto (R), William Pearson (D), Carol McGuire (R), Chuck Grassie (D), Daniel Eaton (D), Patricia Lovejoy (D), as well as Senators Martha Clark, John Reagan, Daniel Innis.

Last year New Hampshire’s full House of Representatives passed a similar bill with a 289 to 58 vote, but it failed to pass the Senate.

According to a WMUR Granite State Poll released July of last year, 61% of New Hampshire voters support legalizing cannabis.

The full text of House Bill 640 can be found by clicking here.

Source:  New Hampshire Committee Passes Bill to Decriminalize Cannabis and Hash appeared first on TheJointBlog.com.

Study: Marijuana Extract Associated With Improved Survival Rates In Glioma Patients

By NORML

Brain tumor patients treated with marijuana extracts have increased survival rates compared to those who go untreated; this is according to newly released research.

Twenty-one patients with recurrent glioblastoma multiforme and who were undergoing conventional anti-cancer treatment participated in the study. Patients received either a proprietary cannabis extract containing a combination of THC and CBD or a placebo.

“[P]atients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort,” the company summarized in a press release. “Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.”

The study’s findings replicate preclinical data demonstrating that the adjunctive use of cannabinoids with temozolomide may be associated with greater anti-cancer activity than the use of conventional therapy alone.

Glioblastoma multiforme is an especially aggressive form of cancer; only 28 percent of patients survive after one year and fewer than four percent surviving five years.